Long-Term Survival Following Ablation of Colorectal Liver Metastases

Iben Rahbek Andersen; Frank Viborg Mortensen; Jakob Kirkegaard; Finn Rasmussen; Dennis Tønner Nielsen; Daniel Willy Kjaer

doi:doi:10.11648/j.js.20180601.13

Long-Term Survival Following Ablation of Colorectal Liver Metastases

Iben Rahbek Andersen, Frank Viborg Mortensen, Jakob Kirkegaard, Finn Rasmussen, Dennis Tønner Nielsen, Daniel Willy Kjaer

Published in Journal of Surgery (Volume 6, Issue 1)

Received: 7 December 2017 Accepted: 19 December 2017 Published: 5 January 2018

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Ablation of colorectal liver metastases (CRLM) in highly selected patients is an option with curative potential. Patient selection and the ablative technique have continued to improve over the years. This study assessed the trends in long-term survival after ablation of CRLM. Methods: We conducted a register-based cohort study of all patients with CRLM referred to ablative treatment by the multidisciplinary team for hepatic diseases at our institution between 2000 and 2014. Patient data used to calculate estimates of survival was retrieved using national registries. Patients were divided into three subgroups according to time of ablation (2000-2004; 2005-2009, and 2010-2014). Survival was defined as the time from the first ablation procedure until death, censoring or end of the follow-up period (December 31, 2015). Results: 741 CRLM ablations were performed in 444 patients. The estimated 5-year survival from first ablation procedure was for 2000-2004: 18.9% (95% CI: 10.7-28.8%); 2005-2009: 31.1% (95% CI: 24.3-38.2%); and 2010-2014: 53.3% (95% CI: 44.3-61.5%). Log rank test showed a statistically significant difference in the survival between the three subgroups (p < 0.001). Conclusion: Survival rates improved from 2000 to 2014 probably owing to multiple factors, including advances in ablation procedures, oncological therapy, and optimized patient selection.

Published in	Journal of Surgery (Volume 6, Issue 1)
DOI	10.11648/j.js.20180601.13
Page(s)	13-18
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2018. Published by Science Publishing Group

Keywords

Survival, Ablation, Radiofrequency/RFA, Microwave/MWA, Colorectal Cancer, Liver Metastases

References

[1]	Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN: New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 2007, 1(1):20-27.
[2]	Eadens MJ, Grothey A: Curable metastatic colorectal cancer. Curr Oncol Rep 2011, 13(3):168-176.
[3]	Abdalla EK, Vauthey J-N, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA: Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases. Annals of surgery 2004, 239(6):818-827.
[4]	Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL: Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases. Annals of surgery 2002, 235(6):759-766.
[5]	Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer. Annals of surgery 1999, 230(3):309.
[6]	Stangl R: Factors influencing the natural history of colorectal liver metastases. The Lancet 1994, 343(8910):1405-1410.
[7]	Gillams A, Goldberg N, Ahmed M, Bale R, Breen D, Callstrom M, Chen MH, Choi BI, de Baere T, Dupuy D, Gangi A, Gervais D, Helmberger T, Jung E-M, Lee F, Lencioni R, Liang P, Livraghi T, Lu D, Meloni F, Pereira P, Piscaglia F, Rhim H, Salem R, Sofocleous C, Solomon SB, Soulen M, Tanaka M, Vogl T, Wood B, Solbiati L: Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. European Radiology 2015, 25(12):3438-3454.
[8]	Jones RP, Jackson R, Dunne DFJ, Malik HZ, Fenwick SW, Poston GJ, Ghaneh P: Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. British Journal of Surgery 2012, 99(4):477-486.
[9]	Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN: Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012, 265(3):958-968.
[10]	Karanicolas PJ, Jarnagin WR, Gonen M, Tuorto S, Allen PJ, DeMatteo RP, D’Angelica MI, Fong Y: Long-term Outcomes Following Tumor Ablation for Treatment of Bilateral Colorectal Liver Metastases. JAMA Surgery 2013, 148(7):597.
[11]	van Amerongen MJ, van der Stok EP, Fütterer JJ, Jenniskens SFM, Moelker A, Grünhagen DJ, Verhoef C, de Wilt JHW: Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation. European Journal of Surgical Oncology (EJSO) 2016, 42(4):523-530.
[12]	Gillams AR, Lees WR: Five-year Survival following Radiofrequency Ablation of Small, Solitary, Hepatic Colorectal Metastases. Journal of Vascular and Interventional Radiology 2008, 19(5):712-717.
[13]	Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, Schlag PM, Punt CJA, Ledermann J, Ruers TJM: Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. European Journal of Cancer 2014, 50(5):912-919.
[14]	Schmidt M, Pedersen L, Sørensen HT: The Danish Civil Registration System as a tool in epidemiology. European journal of epidemiology 2014, 29(8):541-549.
[15]	Gjerstorff ML: The Danish Cancer Registry. Scandinavian Journal of Public Health 2011, 39(7 Suppl):42-45.
[16]	Helweg-Larsen K: The Danish Register of Causes of Death. Scandinavian Journal of Public Health 2011, 39(7 Suppl):26-29.
[17]	Martin RC, Scoggins CR, McMasters KM: Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Annals of surgical oncology 2010, 17(1):171-178.
[18]	Carrafiello G, Laganà D, Mangini M, Fontana F, Dionigi G, Boni L, Rovera F, Cuffari S, Fugazzola C: Microwave tumors ablation: Principles, clinical applications and review of preliminary experiences. International Journal of Surgery 2008, 6:S65-S69.
[19]	Poulou LS: Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World Journal of Hepatology 2015, 7(8):1054.
[20]	Clark ME, Smith RR: Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol 2014, 5(5):374-387.
[21]	Siperstein AE, Berber E, Ballem N, Parikh RT: Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Annals of surgery 2007, 246(4):559-565; discussion 565-557.
[22]	Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST, Wong J: Learning Curve for Radiofrequency Ablation of Liver Tumors. Annals of surgery 2004, 239(4):441-449.
[23]	Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR: Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical Oncology 2009, 27(22):3677-3683.
[24]	Sørensen SM, Mortensen FV, Nielsen DT: Radiofrequency Ablation of Colorectal Liver Metastases: Long-Term Survival. Acta Radiologica 2007, 48(3):253-258.
[25]	Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, Alago W, Durack JC, Maybody M, Brody LA, Siegelbaum RH, D'Angelica MI, Jarnagin WR, Solomon SB, Kemeny NE, Sofocleous CT: Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology 2016, 278(2):601-611.
[26]	Scheele J, Stangl R, Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. British Journal of Surgery 1990, 77(11):1241-1246.

Cite This Article

Plain Text BibTeX RIS

APA Style

Iben Rahbek Andersen, Frank Viborg Mortensen, Jakob Kirkegaard, Finn Rasmussen, Dennis Tønner Nielsen, et al. (2018). Long-Term Survival Following Ablation of Colorectal Liver Metastases. Journal of Surgery, 6(1), 13-18. https://doi.org/10.11648/j.js.20180601.13

Copy | Download

ACS Style

Iben Rahbek Andersen; Frank Viborg Mortensen; Jakob Kirkegaard; Finn Rasmussen; Dennis Tønner Nielsen, et al. Long-Term Survival Following Ablation of Colorectal Liver Metastases. J. Surg. 2018, 6(1), 13-18. doi: 10.11648/j.js.20180601.13

Copy | Download

AMA Style

Iben Rahbek Andersen, Frank Viborg Mortensen, Jakob Kirkegaard, Finn Rasmussen, Dennis Tønner Nielsen, et al. Long-Term Survival Following Ablation of Colorectal Liver Metastases. J Surg. 2018;6(1):13-18. doi: 10.11648/j.js.20180601.13

Copy | Download

@article{10.11648/j.js.20180601.13,
  author = {Iben Rahbek Andersen and Frank Viborg Mortensen and Jakob Kirkegaard and Finn Rasmussen and Dennis Tønner Nielsen and Daniel Willy Kjaer},
  title = {Long-Term Survival Following Ablation of Colorectal Liver Metastases},
  journal = {Journal of Surgery},
  volume = {6},
  number = {1},
  pages = {13-18},
  doi = {10.11648/j.js.20180601.13},
  url = {https://doi.org/10.11648/j.js.20180601.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.js.20180601.13},
  abstract = {Introduction: Ablation of colorectal liver metastases (CRLM) in highly selected patients is an option with curative potential. Patient selection and the ablative technique have continued to improve over the years. This study assessed the trends in long-term survival after ablation of CRLM. Methods: We conducted a register-based cohort study of all patients with CRLM referred to ablative treatment by the multidisciplinary team for hepatic diseases at our institution between 2000 and 2014. Patient data used to calculate estimates of survival was retrieved using national registries. Patients were divided into three subgroups according to time of ablation (2000-2004; 2005-2009, and 2010-2014). Survival was defined as the time from the first ablation procedure until death, censoring or end of the follow-up period (December 31, 2015). Results: 741 CRLM ablations were performed in 444 patients. The estimated 5-year survival from first ablation procedure was for 2000-2004: 18.9% (95% CI: 10.7-28.8%); 2005-2009: 31.1% (95% CI: 24.3-38.2%); and 2010-2014: 53.3% (95% CI: 44.3-61.5%). Log rank test showed a statistically significant difference in the survival between the three subgroups (p < 0.001). Conclusion: Survival rates improved from 2000 to 2014 probably owing to multiple factors, including advances in ablation procedures, oncological therapy, and optimized patient selection.},
 year = {2018}
}

Copy | Download

TY - JOUR
T1 - Long-Term Survival Following Ablation of Colorectal Liver Metastases
AU - Iben Rahbek Andersen
AU - Frank Viborg Mortensen
AU - Jakob Kirkegaard
AU - Finn Rasmussen
AU - Dennis Tønner Nielsen
AU - Daniel Willy Kjaer
Y1 - 2018/01/05
PY - 2018
N1 - https://doi.org/10.11648/j.js.20180601.13
DO - 10.11648/j.js.20180601.13
T2 - Journal of Surgery
JF - Journal of Surgery
JO - Journal of Surgery
SP - 13
EP - 18
PB - Science Publishing Group
SN - 2330-0930
UR - https://doi.org/10.11648/j.js.20180601.13
AB - Introduction: Ablation of colorectal liver metastases (CRLM) in highly selected patients is an option with curative potential. Patient selection and the ablative technique have continued to improve over the years. This study assessed the trends in long-term survival after ablation of CRLM. Methods: We conducted a register-based cohort study of all patients with CRLM referred to ablative treatment by the multidisciplinary team for hepatic diseases at our institution between 2000 and 2014. Patient data used to calculate estimates of survival was retrieved using national registries. Patients were divided into three subgroups according to time of ablation (2000-2004; 2005-2009, and 2010-2014). Survival was defined as the time from the first ablation procedure until death, censoring or end of the follow-up period (December 31, 2015). Results: 741 CRLM ablations were performed in 444 patients. The estimated 5-year survival from first ablation procedure was for 2000-2004: 18.9% (95% CI: 10.7-28.8%); 2005-2009: 31.1% (95% CI: 24.3-38.2%); and 2010-2014: 53.3% (95% CI: 44.3-61.5%). Log rank test showed a statistically significant difference in the survival between the three subgroups (p < 0.001). Conclusion: Survival rates improved from 2000 to 2014 probably owing to multiple factors, including advances in ablation procedures, oncological therapy, and optimized patient selection.
VL - 6
IS - 1
ER -

Copy | Download

Author Information

Iben Rahbek Andersen

Department of Radiology, Aarhus University Hospital, Aarhus, Denmark
Frank Viborg Mortensen

Department of Surgery, Aarhus University Hospital, Aarhus, Denmark
Jakob Kirkegaard

Department of Surgery, Aarhus University Hospital, Aarhus, Denmark
Finn Rasmussen

Department of Radiology, Aarhus University Hospital, Aarhus, Denmark
Dennis Tønner Nielsen
Daniel Willy Kjaer

Department of Surgery, Aarhus University Hospital, Aarhus, Denmark

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Iben Rahbek Andersen, Frank Viborg Mortensen, Jakob Kirkegaard, Finn Rasmussen, Dennis Tønner Nielsen, et al. (2018). Long-Term Survival Following Ablation of Colorectal Liver Metastases. Journal of Surgery, 6(1), 13-18. https://doi.org/10.11648/j.js.20180601.13

Copy | Download

ACS Style

Iben Rahbek Andersen; Frank Viborg Mortensen; Jakob Kirkegaard; Finn Rasmussen; Dennis Tønner Nielsen, et al. Long-Term Survival Following Ablation of Colorectal Liver Metastases. J. Surg. 2018, 6(1), 13-18. doi: 10.11648/j.js.20180601.13

Copy | Download

AMA Style

Iben Rahbek Andersen, Frank Viborg Mortensen, Jakob Kirkegaard, Finn Rasmussen, Dennis Tønner Nielsen, et al. Long-Term Survival Following Ablation of Colorectal Liver Metastases. J Surg. 2018;6(1):13-18. doi: 10.11648/j.js.20180601.13

Copy | Download

@article{10.11648/j.js.20180601.13,
  author = {Iben Rahbek Andersen and Frank Viborg Mortensen and Jakob Kirkegaard and Finn Rasmussen and Dennis Tønner Nielsen and Daniel Willy Kjaer},
  title = {Long-Term Survival Following Ablation of Colorectal Liver Metastases},
  journal = {Journal of Surgery},
  volume = {6},
  number = {1},
  pages = {13-18},
  doi = {10.11648/j.js.20180601.13},
  url = {https://doi.org/10.11648/j.js.20180601.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.js.20180601.13},
  abstract = {Introduction: Ablation of colorectal liver metastases (CRLM) in highly selected patients is an option with curative potential. Patient selection and the ablative technique have continued to improve over the years. This study assessed the trends in long-term survival after ablation of CRLM. Methods: We conducted a register-based cohort study of all patients with CRLM referred to ablative treatment by the multidisciplinary team for hepatic diseases at our institution between 2000 and 2014. Patient data used to calculate estimates of survival was retrieved using national registries. Patients were divided into three subgroups according to time of ablation (2000-2004; 2005-2009, and 2010-2014). Survival was defined as the time from the first ablation procedure until death, censoring or end of the follow-up period (December 31, 2015). Results: 741 CRLM ablations were performed in 444 patients. The estimated 5-year survival from first ablation procedure was for 2000-2004: 18.9% (95% CI: 10.7-28.8%); 2005-2009: 31.1% (95% CI: 24.3-38.2%); and 2010-2014: 53.3% (95% CI: 44.3-61.5%). Log rank test showed a statistically significant difference in the survival between the three subgroups (p < 0.001). Conclusion: Survival rates improved from 2000 to 2014 probably owing to multiple factors, including advances in ablation procedures, oncological therapy, and optimized patient selection.},
 year = {2018}
}

Copy | Download